Cleerly Strengthens Clinical Validation and Reimbursement Tailwinds for AI Cardiac Imaging

Cleerly is the developer of an AI-powered cardiac imaging platform focused on quantitative coronary CT analysis, and this is a weekly summary of its notable news. The company continued to build clinical and commercial momentum through new validation data and enhanced visibility at a major cardiology conference.

Cleerly highlighted new data from the INVICTUS registry showing 94.4% agreement between its AI-based quantitative coronary CT (AI-QCT) technology and intravascular ultrasound, an invasive gold-standard for coronary plaque quantification. The multi-center registry included 17 participating sites, supporting the credibility and generalizability of the findings across diverse clinical settings.

This high concordance positions AI-QCT as a clinically competitive, less invasive alternative to traditional intravascular imaging for plaque characterization. The strengthened evidence base may help Cleerly advance discussions with physicians, health systems, and payors about integrating its platform into routine cardiology workflows.

In parallel, Cleerly underscored a shifting reimbursement environment tied to its technology, pointing to a new Category I CPT code and expanded insurance coverage. These developments suggest a more structured pathway for payment of AI-enabled coronary CT analysis, which could support broader adoption if clinical demand continues to build.

The company is also leveraging its presence at the American College of Cardiology’s ACC.26 conference in New Orleans, where executives and clinical leaders are hosting onsite meet-and-greet sessions at Booth #1645. Cleerly plans to demonstrate how its software generates 3D coronary artery models and color-coded plaque maps to augment coronary CT angiography.

Conference visibility at ACC.26 is designed to deepen engagement with cardiologists, guideline influencers, and provider organizations, potentially translating into new clinical deployments over time. While no specific financial metrics or new contracts were disclosed, the combination of strong concordance data, emerging reimbursement tailwinds, and active outreach supports Cleerly’s positioning in AI-driven cardiovascular diagnostics.

Overall, the week reflected continued progress for Cleerly in validating its AI-QCT platform clinically while laying groundwork for improved reimbursement and commercial expansion in cardiac imaging and preventive cardiology.